This is great news!
The important facts to know about this trial: it is first line (anthracycline naïve pts) and only about 15% of soft tissue sarcomas respond to anthracyclines (i.e. doxorubicin).
It is also relatively rare. So a successful trial will be a slam dunk for orphan drug designation from the FDA.
Given the pre-clinical evidence and the evidence from the compassionate use programme, confidence should be very high for a successful trial.
Sarcoma trial to start Nov 15, page-3
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
